FIA
BOLD

FNY Investment Advisers’s Boundless Bio BOLD Stock Holding History

FNY Investment Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-660
Closed -$9 – 861
2024
Q1 		$9 Buy
+660
New +$9.4K 0.01% 469

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

FNY Investment Advisers's BOLD Position: Q2 2024 in Review

FNY Investment Advisers sold out of Boundless Bio (BOLD) in Q2 2024, closing a stake of 660 shares — an estimated $9 sold.

FNY Investment Advisers first reported a position in BOLD in Q1 2024 and held it in 1 quarter. The position peaked at $9 in Q1 2024. 47 funds tracked by Wall St. Rank hold BOLD as of Q2 2024.

  • FNY Investment Advisers reported no remaining Boundless Bio position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 660 Boundless Bio shares in Q2 2024, an estimated $9.
  • FNY Investment Advisers first reported a position in Boundless Bio in Q1 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Boundless Bio position peaked at $9 in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.